Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1 , plus 5-FU day 1 and 8 , and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8 , c
Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma. A southwest oncology group study
โ Scribed by Stephen E. Jones; Petre N. Grozea; Earl N. Metz; Arthur Haut; Ronald L. Stephens; Francis S. Morrison; James J. Butler; Gerald E. Byrne Jr.; Thomas E. Moon; Richard Fisher; Constance L. Haskins; Charles A. Coltman Jr.
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- English
- Weight
- 691 KB
- Volume
- 43
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract Eighteen (72%) of 25 evaluable and previously untreated patients with adult acute lymphoblastic leukemia entered complete remission (CR) following induction therapy with Adriamycin, vincristine, and prednisone in a Southwest Oncology Group study. Remission maintenance therapy with metho
## Abstract The Southwest Oncology Group performed a randomized study comparing combination chemotherapy alone versus combination chemotherapy plus BCG versus DTIC plus BCG in the treatment of disseminated malignant melanoma. A 31% response rate was noted with combination chemotherapy alone, a 27%